KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Payables (2016 - 2025)

Historic Payables for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $15.4 million.

  • Halozyme Therapeutics' Payables rose 2389.1% to $15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 2389.1%. This contributed to the annual value of $10.2 million for FY2024, which is 1326.17% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Payables stood at $15.4 million for Q3 2025, which was up 2389.1% from $18.7 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Payables ranged from a high of $20.1 million in Q1 2025 and a low of $535000.0 during Q1 2021
  • Its 5-year average for Payables is $11.3 million, with a median of $12.2 million in 2022.
  • As far as peak fluctuations go, Halozyme Therapeutics' Payables tumbled by 9356.97% in 2021, and later surged by 104815.06% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Payables (Quarter) stood at $1.5 million in 2021, then soared by 1048.15% to $17.7 million in 2022, then plummeted by 33.22% to $11.8 million in 2023, then fell by 13.26% to $10.2 million in 2024, then surged by 49.87% to $15.4 million in 2025.
  • Its Payables was $15.4 million in Q3 2025, compared to $18.7 million in Q2 2025 and $20.1 million in Q1 2025.